Premium
Histone deacetylase inhibitor for NUT midline carcinoma
Author(s) -
Maher Ossama M.,
Christensen Anthony M.,
Yedururi Sireesha,
Bell Diana,
Tarek Nidale
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25350
Subject(s) - medicine , vorinostat , histone deacetylase inhibitor , blood cancer , nut , histone deacetylase , cancer research , chemotherapy , cancer , oncology , histone , gene , genetics , biology , structural engineering , engineering
NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17‐year‐old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration. Pediatr Blood Cancer 2015;62:715–717. © 2015 Wiley Periodicals, Inc.